Research on Autism Spectrum Disorders (R21 Clinical Trial Optional)
ID: 332515Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $200K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/332515

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-21-200.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research on Autism Spectrum Disorders (ASD) through the R21 Clinical Trial Optional grant mechanism. This initiative aims to support exploratory and innovative research that elucidates the etiology, epidemiology, diagnosis, and optimal service delivery related to ASD, encouraging applications that do not require preliminary data. The program is crucial for advancing understanding and improving services for individuals with ASD, with grants available up to $275,000 for a two-year period, contingent on the quality of applications and available funds. Interested applicants must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PA-21-200-Full-Announcement.html
    PA-21-200.html
    The National Institutes of Health (NIH) under the Department of Health and Human Services has released a funding opportunity announcement (FOA) for research on Autism Spectrum Disorders (ASD) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative invites applications focused on understanding the causes, epidemiology, diagnosis, and delivery of services relevant to ASD. The FOA emphasizes exploratory and innovative research, requiring no preliminary data but encouraging proposals that could lead to significant advancements in the field. Key research areas include genetic and environmental epidemiology, brain mechanisms underlying behaviors associated with ASD, cognitive science related to social communication, and services research aimed at improving service delivery for ASD individuals. Grants of up to $275,000 for two years will be awarded, contingent on available funds and the quality of applications. Eligible applicants encompass a wide range of entities including higher education institutions, nonprofits, and government agencies. The application review process will assess significance, innovation, investigator qualifications, and approaches to ensure their potential impact on ASD research and treatment.
    Similar Opportunities
    Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on Autism Spectrum Disorders (R03 Clinical Trial Optional)" aimed at promoting research on Autism Spectrum Disorders (ASD). This initiative encourages applications that investigate various aspects of ASD, including its etiology, epidemiology, diagnosis, and service delivery methods, through small, well-defined projects that can be completed within two years. The R03 grant program is particularly significant as it addresses a critical public health issue affecting many individuals and families, allowing for both clinical and non-clinical trials without the requirement for preliminary data in pilot studies. Interested applicants can apply for grants of up to $50,000, with the application deadline set for November 16, 2024. For further details, applicants may contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the funding announcement page at http://grants.nih.gov/grants/guide/pa-files/PA-21-199.html.
    Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Autism Spectrum Disorders (ASD) under the title "Research on Autism Spectrum Disorders (R01 Clinical Trial Optional)." This initiative aims to support research that elucidates the etiology, epidemiology, diagnosis, and optimal service delivery methods related to ASD, encouraging applications from a diverse range of eligible organizations, including higher education institutions, non-profits, and tribal governments. The research projects may include clinical trials exploring biological or behavioral processes associated with ASD, with a focus on areas such as epidemiological studies, screening methods, and services research to enhance care for individuals with ASD. Applications are due by January 25, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries or assistance.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) grant. This funding opportunity aims to support projects that address critical needs for clinical trial readiness in rare diseases, specifically by facilitating the development of biomarkers and clinical outcome measures essential for trial design. The initiative is particularly important for advancing research on diseases affecting fewer than 200,000 individuals in the U.S., enhancing the likelihood of successful clinical trials. Applicants can request up to $275,000 over two years, with a submission deadline of October 17, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html.
    Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Animal Models and Related Biological Materials for Down Syndrome Research" under the INCLUDE Project. This initiative aims to support exploratory and innovative research focused on developing and characterizing animal models and biological materials that are essential for Down syndrome (DS) studies, with an emphasis on improving access to these resources and enhancing the rigor of preclinical research. The funding opportunity is particularly significant as it addresses critical gaps in DS research, encouraging projects that utilize advanced technologies such as artificial intelligence and machine learning. Eligible applicants can receive up to $200,000 for a two-year project period, with applications due in March, June, October, and February each year, and the announcement set to expire on January 8, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.